Shares of Grail, Inc. (NASDAQ:GRAL - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $52.60, but opened at $49.04. Grail shares last traded at $49.32, with a volume of 363,066 shares.
Wall Street Analysts Forecast Growth
GRAL has been the subject of several recent analyst reports. Wolfe Research started coverage on Grail in a research note on Friday, November 15th. They set a "peer perform" rating for the company. Morgan Stanley initiated coverage on Grail in a research note on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 price objective for the company.
Read Our Latest Research Report on GRAL
Grail Stock Down 14.7 %
The business's 50 day moving average is $26.32 and its 200-day moving average is $19.06.
Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The company had revenue of $38.25 million during the quarter, compared to analyst estimates of $35.33 million. On average, analysts expect that Grail, Inc. will post -65.16 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new stake in shares of Grail in the 4th quarter valued at approximately $26,000. State of Tennessee Department of Treasury bought a new stake in Grail during the fourth quarter valued at $28,000. Lindbrook Capital LLC acquired a new stake in shares of Grail during the fourth quarter worth $28,000. Sterling Capital Management LLC bought a new position in shares of Grail in the 4th quarter worth about $29,000. Finally, Wellington Shields Capital Management LLC acquired a new position in shares of Grail in the 4th quarter valued at about $33,000.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
